Adjuvant gefitinib presents no overall survival (OS) profit over standard chemotherapy for EGFR-mutant, resected, stage II-IIIA non–small cell lung most cancers (NSCLC), basically basically basically…
Adjuvant gefitinib presents no overall survival (OS) profit over standard chemotherapy for EGFR-mutant, resected, stage II-IIIA non–small cell lung most cancers (NSCLC), basically basically basically…